Muscle-Invasive Bladder Cancer in Non-Curative Patients: A Study on Survival and Palliative Care Needs
Abstract
Simple Summary
Abstract
1. Introduction
2. Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Burger, M.; Catto, J.W.; Dalbagni, G.; Grossman, H.B.; Herr, H.; Karakiewicz, P.; Kassouf, W.; Kiemeney, L.A.; La Vecchia, C.; Shariat, S.; et al. Epidemiology and risk factors of urothelial bladder cancer. Eur. Urol. 2013, 63, 234–241. [Google Scholar] [CrossRef] [PubMed]
- Ferlay, J.; Steliarova-Foucher, E.; Lortet-Tieulent, J.; Rosso, S.; Coebergh, J.W.; Comber, H.; Forman, D.; Bray, F. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur. J. Cancer 2013, 49, 1374–1403. [Google Scholar] [CrossRef] [PubMed]
- Cozar, J.M.; Minana, B.; Palou-Redorta, J.; Medina, R.A.; de la Rosa-Kehrmann, F.; Lozano-Palacio, F.; Ribal-Caparros, M.J.; Hernandez-Fernandez, C.; Castineiras-Fernandez, J.J.; Requena, M.J.; et al. Comparative analysis of the incidence of bladder cancer in the communities of Andalusia, Catalonia and Madrid in 2011. Actas Urol. Esp. 2015, 39, 420–428. [Google Scholar] [CrossRef] [PubMed]
- Cambier, S.; Sylvester, R.J.; Collette, L.; Gontero, P.; Brausi, M.A.; van Andel, G.; Kirkels, W.J.; Silva, F.C.; Oosterlinck, W.; Prescott, S.; et al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1–3 Years of Maintenance Bacillus Calmette-Guerin. Eur. Urol. 2016, 69, 60–69. [Google Scholar] [CrossRef]
- Gontero, P.; Birtle, A.; Capoun, O.; Comperat, E.; Dominguez-Escrig, J.L.; Liedberg, F.; Mariappan, P.; Masson-Lecomte, A.; Mostafid, H.A.; Pradere, B.; et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)-A Summary of the 2024 Guidelines Update. Eur. Urol. 2024. [Google Scholar] [CrossRef]
- Guerrero-Ramos, F.; Subiela, J.D.; Rodriguez-Faba, O.; Aumatell, J.; Manfredi, C.; Bozzini, G.; Romero-Otero, J.; Counago, F. Predicting Recurrence and Progression in Patients with Non-Muscle-Invasive Bladder Cancer: Systematic Review on the Performance of Risk Stratification Models. Bladder Cancer 2022, 8, 339–357. [Google Scholar] [CrossRef]
- Guerrero-Ramos, F.; Boormans, J.L.; Daneshmand, S.; Gontero, P.; Kamat, A.M.; Roupret, M.; Vilaseca, A.; Shariat, S.F. Novel Delivery Systems and Pharmacotherapeutic Approaches for the Treatment of Non-muscle-invasive Bladder Cancer. Eur. Urol. Oncol. 2024. [Google Scholar] [CrossRef] [PubMed]
- Guerrero-Ramos, F.; Alvarez-Maestro, M.; Pinto Marin, A.; Dominguez Escrig, J.L.; Rodriguez Faba, O. Multidisciplinary consensus document on the current treatment of bacille Calmette-Guerin-unresponsive non-muscle invasive bladder tumor. Actas Urol. Esp. 2024, 48, 262–272. [Google Scholar] [CrossRef]
- Alfred Witjes, J.; Max Bruins, H.; Carrion, A.; Cathomas, R.; Comperat, E.; Efstathiou, J.A.; Fietkau, R.; Gakis, G.; Lorch, A.; Martini, A.; et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines. Eur. Urol. 2024, 85, 17–31. [Google Scholar] [CrossRef]
- Bajorin, D.F.; Witjes, J.A.; Gschwend, J.E.; Schenker, M.; Valderrama, B.P.; Tomita, Y.; Bamias, A.; Lebret, T.; Shariat, S.F.; Park, S.H.; et al. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N. Engl. J. Med. 2021, 384, 2102–2114. [Google Scholar] [CrossRef]
- Bellmunt, J.; Hussain, M.; Gschwend, J.E.; Albers, P.; Oudard, S.; Castellano, D.; Daneshmand, S.; Nishiyama, H.; Majchrowicz, M.; Degaonkar, V.; et al. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): A multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021, 22, 525–537. [Google Scholar] [CrossRef] [PubMed]
- Necchi, A.; Anichini, A.; Raggi, D.; Briganti, A.; Massa, S.; Luciano, R.; Colecchia, M.; Giannatempo, P.; Mortarini, R.; Bianchi, M.; et al. Pembrolizumab as Neoadjuvant Therapy before Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. J. Clin. Oncol. 2018, 36, 3353–3360. [Google Scholar] [CrossRef] [PubMed]
- Powles, T.; Assaf, Z.J.; Davarpanah, N.; Banchereau, R.; Szabados, B.E.; Yuen, K.C.; Grivas, P.; Hussain, M.; Oudard, S.; Gschwend, J.E.; et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature 2021, 595, 432–437. [Google Scholar] [CrossRef] [PubMed]
- Siech, C.; Jannello, L.M.I.; de Angelis, M.; Di Bello, F.; Goyal, J.A.; Tian, Z.; Saad, F.; Shariat, S.F.; Longo, N.; de Cobelli, O.; et al. Critical care therapy use after radical cystectomy in patients with non-metastatic bladder cancer. Curr. Probl. Surg. 2024, 61, 101526. [Google Scholar] [CrossRef] [PubMed]
- Rey-Cardenas, M.; Guerrero-Ramos, F.; Gomez de Liano Lista, A.; Carretero-Gonzalez, A.; Bote, H.; Herrera-Juarez, M.; Carril-Ajuria, L.; Martin-Soberon, M.; Sepulveda, J.M.; Billalabeitia, E.G.; et al. Recent advances in neoadjuvant immunotherapy for urothelial bladder cancer: What to expect in the near future. Cancer Treat. Rev. 2021, 93, 102142. [Google Scholar] [CrossRef]
- Garde, H.; Ciappara, M.; Galante, I.; Fuentes Ferrer, M.; Gomez, A.; Blazquez, J.; Moreno, J. Radical cystectomy in octogenarian patients: A difficult decision to take. Urol. Int. 2015, 94, 390–393. [Google Scholar] [CrossRef]
- Horovitz, D.; Turker, P.; Bostrom, P.J.; Mirtti, T.; Nurmi, M.; Kuk, C.; Kulkarni, G.; Fleshner, N.E.; Finelli, A.; Jewett, M.A.; et al. Does patient age affect survival after radical cystectomy? BJU Int. 2012, 110, E486–E493. [Google Scholar] [CrossRef]
- Life Expectancy and Healthy Life Expectancy (World Health Organization). Available online: http://apps.who.int/gho/data/view.main.SDG2016LEXv?lang=en (accessed on 27 August 2024).
- Hagerty, R.G.; Butow, P.N.; Ellis, P.A.; Lobb, E.A.; Pendlebury, S.; Leighl, N.; Goldstein, D.; Lo, S.K.; Tattersall, M.H. Cancer patient preferences for communication of prognosis in the metastatic setting. J. Clin. Oncol. 2004, 22, 1721–1730. [Google Scholar] [CrossRef]
- Innes, S.; Payne, S. Advanced cancer patients’ prognostic information preferences: A review. Palliat Med. 2009, 23, 29–39. [Google Scholar] [CrossRef]
- Martini, A.; Sfakianos, J.P.; Renstrom-Koskela, L.; Mortezavi, A.; Falagario, U.G.; Egevad, L.; Hosseini, A.; Mehrazin, R.; Galsky, M.D.; Steineck, G.; et al. The natural history of untreated muscle-invasive bladder cancer. BJU Int. 2020, 125, 270–275. [Google Scholar] [CrossRef]
- Westergren, D.O.; Gardmark, T.; Lindhagen, L.; Chau, A.; Malmstrom, P.U. A Nationwide, Population Based Analysis of Patients with Organ Confined, Muscle Invasive Bladder Cancer Not Receiving Curative Intent Therapy in Sweden from 1997 to 2014. J. Urol. 2019, 202, 905–912. [Google Scholar] [CrossRef] [PubMed]
- Ogawa, K.; Shimizu, Y.; Uketa, S.; Utsunomiya, N.; Kanamaru, S. Prognosis of patients with muscle invasive bladder cancer who are intolerable to receive any anti-cancer treatment. Cancer Treat Res. Commun. 2020, 24, 100195. [Google Scholar] [CrossRef] [PubMed]
- Balar, A.V.; Castellano, D.E.; Grivas, P.; Vaughn, D.J.; Powles, T.; Vuky, J.; Fradet, Y.; Lee, J.L.; Fong, L.; Vogelzang, N.J.; et al. Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: Results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up. Ann. Oncol. 2023, 34, 289–299. [Google Scholar] [CrossRef]
- Di Bello, F.; Siech, C.; Jannello, L.M.I.; de Angelis, M.; Rodriguez Penaranda, N.; Tian, Z.; Goyal, J.A.; Baudo, A.; Colla Ruvolo, C.; Califano, G.; et al. Contemporary survival in metastatic bladder cancer patients: A population-based study. Int. J. Cancer 2024, 155, 1762–1768. [Google Scholar] [CrossRef]
- Powles, T.; Park, S.H.; Voog, E.; Caserta, C.; Valderrama, B.P.; Gurney, H.; Kalofonos, H.; Radulovic, S.; Demey, W.; Ullen, A.; et al. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N. Engl. J. Med. 2020, 383, 1218–1230. [Google Scholar] [CrossRef] [PubMed]
- Powles, T.; Valderrama, B.P.; Gupta, S.; Bedke, J.; Kikuchi, E.; Hoffman-Censits, J.; Iyer, G.; Vulsteke, C.; Park, S.H.; Shin, S.J.; et al. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N. Engl. J. Med. 2024, 390, 875–888. [Google Scholar] [CrossRef]
- Siefker-Radtke, A.O.; Necchi, A.; Park, S.H.; Garcia-Donas, J.; Huddart, R.A.; Burgess, E.F.; Fleming, M.T.; Rezazadeh Kalebasty, A.; Mellado, B.; Varlamov, S.; et al. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: Long-term follow-up of a phase 2 study. Lancet Oncol. 2022, 23, 248–258. [Google Scholar] [CrossRef]
- Van der Heijden, M.S.; Sonpavde, G.; Powles, T.; Necchi, A.; Burotto, M.; Schenker, M.; Sade, J.P.; Bamias, A.; Beuzeboc, P.; Bedke, J.; et al. Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma. N. Engl. J. Med. 2023, 389, 1778–1789. [Google Scholar] [CrossRef]
- Tyson, M.D.; Morris, D.; Palou, J.; Rodriguez, O.; Mir, M.C.; Dickstein, R.J.; Guerrero-Ramos, F.; Scarpato, K.R.; Hafron, J.M.; Messing, E.M.; et al. Safety, Tolerability, and Preliminary Efficacy of TAR-200 in Patients with Muscle-invasive Bladder Cancer Who Refused or Were Unfit for Curative-intent Therapy: A Phase 1 Study. J. Urol. 2023, 209, 890–900. [Google Scholar] [CrossRef]
- Monsky, W.L.; Molloy, C.; Jin, B.; Nolan, T.; Fernando, D.; Loh, S.; Li, C.S. Quality-of-life assessment after palliative interventions to manage malignant ureteral obstruction. Cardiovasc. Interv. Radiol. 2013, 36, 1355–1363. [Google Scholar] [CrossRef]
- Canter, D.; Guzzo, T.J.; Resnick, M.J.; Brucker, B.; Vira, M.; Chen, Z.; Tomaszewski, J.; VanArsdalen, K.; Wein, A.J.; Malkowicz, S.B. Hydronephrosis is an independent predictor of poor clinical outcome in patients treated for muscle-invasive transitional cell carcinoma with radical cystectomy. Urology 2008, 72, 379–383. [Google Scholar] [CrossRef] [PubMed]
- Stimson, C.J.; Cookson, M.S.; Barocas, D.A.; Clark, P.E.; Humphrey, J.E.; Patel, S.G.; Smith, J.A., Jr.; Chang, S.S. Preoperative hydronephrosis predicts extravesical and node positive disease in patients undergoing cystectomy for bladder cancer. J. Urol. 2010, 183, 1732–1737. [Google Scholar] [CrossRef] [PubMed]
- Izquierdo, L.; Peri, L.; Leon, P.; Ramirez-Backhaus, M.; Manning, T.; Alcaraz, A.; Roupret, M.; Solsona, E.; Rubio, J.; Sengupta, S.; et al. The role of cystectomy in elderly patients—A multicentre analysis. BJU. Int. 2015, 116 (Suppl. S3), 73–79. [Google Scholar] [CrossRef] [PubMed]
n = 142 | |
---|---|
Age, median (±SD) | 79.4 (±7.8) |
Sex, n (%) male | 124 (87.3) |
Charlson comorbidity index, Median (±SD) | 9.8 (±7.1) |
New diagnosis, n (%) | 88 (61.2) |
Histology, n (%) | |
Urothelial | 134 (94.4) |
Epidermoid | 8 (5.6) |
Clinical stage at diagnosis, n (%) | |
Localized | 84 (59.2) |
Nodal (N1–N3) | 25 (17.6) |
Metastatic (M1a–M1b) | 33 (23.2) |
Hydronephrosis at diagnosis, n (%) | 70 (49.3) |
Reason for no curative intent, n (%) | |
Comorbidities | 57 (40.1) |
Advanced clinical stage | 52 (36.6) |
Age | 25 (17.6) |
Patient/relatives’ refusal | 6 (4.2) |
Unknown | 2 (1.5) |
Treatment offered, n (%) | |
Observation | 88 (61.9) |
Palliative radiotherapy | 20 (14.1) |
Cutaneous ureterostomy | 6 (4.2) |
Transurethral resection of bladder tumor | 4 (2.8) |
Palliative chemotherapy (carboplatin-gemcitabine or gemcitabine alone) | 17 (12.0) |
Palliative chemo-radiotherapy | 7 (5.0) |
Variable | Univariate Analysis | Multivariate Analysis | ||
---|---|---|---|---|
HR (CI 95%) | p | HR (CI 95%) | p | |
Male sex | 0.69 (0.37–1.28) | 0.25 | 0.61 (0.33–1.14) | 0.12 |
Stage | ||||
Nodal (N1–N3) vs. Localized | 1.39 (0.80–2.42) | 0.24 | 1.46 (0.84–2.58) | 0.18 |
Metastatic (M1a–M1b) vs. Localized | 2.73 (1.71–4.35) | <0.001 | 2.06 (1.09–3.86) | 0.025 |
Hydronephrosis at diagnosis | 1.83 (1.22–2.75) | 0.003 | 1.91 (1.26–2.89) | 0.002 |
Reason for no curative intent | ||||
Stage vs. Comorbidities | 1.45 (0.94–2.24) | 0.09 | 1.17 (0.54–2.59) | 0.68 |
Age vs. Comorbidities | 0.43 (0.21–0.86) | 0.017 | 0.49 (0.21–0.97) | 0.042 |
Age, ≥80 | 0.79 (0.53–1.19) | 0.26 | 0.82 (0.53–1.26) | 0.37 |
Charlson comorbidity index, ≥9 | 1.77 (1.18–2.65) | 0.005 | 1.35 (0.78–2.32) | 0.28 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Guerrero-Ramos, F.; González-Padilla, D.A.; Pérez-Cadavid, S.; García-Rojo, E.; Tejido-Sánchez, Á.; Hernández-Arroyo, M.; Gómez-Cañizo, C.; Rodríguez-Antolín, A. Muscle-Invasive Bladder Cancer in Non-Curative Patients: A Study on Survival and Palliative Care Needs. Cancers 2024, 16, 3330. https://doi.org/10.3390/cancers16193330
Guerrero-Ramos F, González-Padilla DA, Pérez-Cadavid S, García-Rojo E, Tejido-Sánchez Á, Hernández-Arroyo M, Gómez-Cañizo C, Rodríguez-Antolín A. Muscle-Invasive Bladder Cancer in Non-Curative Patients: A Study on Survival and Palliative Care Needs. Cancers. 2024; 16(19):3330. https://doi.org/10.3390/cancers16193330
Chicago/Turabian StyleGuerrero-Ramos, Félix, Daniel Antonio González-Padilla, Santiago Pérez-Cadavid, Esther García-Rojo, Ángel Tejido-Sánchez, Mario Hernández-Arroyo, Carmen Gómez-Cañizo, and Alfredo Rodríguez-Antolín. 2024. "Muscle-Invasive Bladder Cancer in Non-Curative Patients: A Study on Survival and Palliative Care Needs" Cancers 16, no. 19: 3330. https://doi.org/10.3390/cancers16193330
APA StyleGuerrero-Ramos, F., González-Padilla, D. A., Pérez-Cadavid, S., García-Rojo, E., Tejido-Sánchez, Á., Hernández-Arroyo, M., Gómez-Cañizo, C., & Rodríguez-Antolín, A. (2024). Muscle-Invasive Bladder Cancer in Non-Curative Patients: A Study on Survival and Palliative Care Needs. Cancers, 16(19), 3330. https://doi.org/10.3390/cancers16193330